TheEdgeResearch
Home / Stocks / DMIIU

Drugs Made In America Acquisition II Corp. Unit (DMIIU)

NASDAQ Financial Services Shell Companies
$10.17 ▲ +0.20%
Market Cap
$707.3M
Sector
Financial Services
Industry
Shell Companies
Beta
0.06
52-Wk Range
9.935-10.8
CEO
Roger Bendelac
Country
US
Currency
USD

Drugs Made In America Acquisition II Corp. Unit operates in the Shell Companies industry of the Financial Services sector, headquartered in New York, NY, US. The stock last traded at $10.17, up 0.20% on the session, giving a market capitalisation of $707.3M. Its beta of 0.06 implies it has historically moved less than the broad market.

Company profile
Exchange
NASDAQ Global Select
Employees
2
IPO date
2025-09-25
Headquarters
New York, NY, US
About Drugs Made In America Acquisition II Corp. Unit

DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing. Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.

Comparable companies

Drugs Made In America Acquisition II Corp. Unit is most often compared with the following Financial Services names:

EICGAINGAMMSIFNCDLNEWTOCCI
More research on DMIIU
DMIIU technical analysis DMIIU TheEdge Score Compare against peers
Open full interactive analysis & DCF →